Adverse events and drug-drug interactions of sodium glucose co-transporter 2 inhibitors in patients treated for heart failure.

Claudia StöllbergerJosef FinstererBirke Schneider

Published in: Expert review of cardiovascular therapy (2023)

Guidelines recommend treatmentwith SGLT2-I for CHF but no data on AE during long-term therapy and only littleinformation on DDI are available, which stresses the need for further research.Evidence-based recommendations for ketoacidosis-prevention are desirable.

Keyphrases

heart failure
clinical practice
electronic health record
big data
atrial fibrillation
acute heart failure
cardiac resynchronization therapy
stem cells
emergency department
machine learning
mesenchymal stem cells